Developer docs
API playgroundTry for free, no card

Search company profiles

Curacle

Full company profile

uuid000cn54

Namestring
Curacle
Legal namestring
Curacle Co., Ltd. (주식회사 큐라클)
Websiteurl
curacle.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Curacle Co., Ltd. is a clinical-stage Korean biopharmaceutical company founded in 2016 and listed on KOSDAQ (ticker 365270), headquartered in Seocho-gu, Seoul. It develops first-in-class therapies that restore microvascular function in aging and chronic diseases by targeting endothelial dysfunction, operating two proprietary platforms: the SOLVADYS® small-molecule platform and the EAGLES® antibody platform accessed through its strategic partner MabTics (in which Curacle holds a 19.5% equity stake). Its nine-asset pipeline spans retinal diseases (Rivasterat/CU06, MT-103), renal indications (CU01, MT-101, CP01-R01 for veterinary CKD), neurodegeneration (CU71 BBB stabilizer for Alzheimer's), inflammatory bowel disease (MT-105), and antithrombotics (MT-201, MT-202), with Rivasterat receiving the WHO INN in May 2025 (first '-sterat' class endothelial dysfunction blocker) and MT-103 demonstrating superior preclinical vascular stabilization versus Vabysmo (faricimab).

The company operates a capital-light out-licensing business model, executing global technology-transfer deals with pharmaceutical partners who fund development and commercialization. The flagship MT-103 bispecific antibody was licensed to US NewCo Memento Medicines in May 2026 in a deal valued up to $1.07775B (approximately 1.56 trillion KRW), with Curacle's 50% share through MabTics amounting to approximately $538.87M in attributable deal value. Curacle received $4M in cash plus $0.75M in Memento equity as the upfront share, with $82.25M in development/regulatory milestones and $987.5M in commercial milestones remaining. To diversify revenue beyond milestone-dependent licensing, Curacle completed an absorption merger with Daesung Pharmtech on January 28, 2026, internalizing an active pharmaceutical ingredient (API) business that supplies raw materials, wholesale, and reagents to pharmaceutical manufacturers. Additional revenue streams include veterinary product sales upon CP01-R01 approval, future licensing of CU01, CU06, MT-101, MT-201 and MT-202, and API manufacturing scale-up via the April 2025 MOU with Daejung Pharma.

Short descriptiontext

Curacle is a clinical-stage Korean biopharmaceutical company developing first-in-class small molecule and antibody therapies that restore microvascular function in retinal, renal, neurodegenerative, and thrombotic diseases, monetizing via out-licensing to global pharma and a newly integrated API business.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeocho, South Korea
HQ citystring
Seocho
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical development, microvascular therapeutics, endothelial dysfunction drugs, drug out-licensing, clinical-stage biotechnology
Industry4 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing - MT-103
TypeLicensing Royalties
Description

Up to $1.07775 billion deal with Memento Medicines including $8M upfront, up to $82.25M development/regulatory milestones, up to $987.5M commercial milestones. Curacle's 50% share amounts to $538.87M attributable revenue.

curacle.com
2API (Active Pharmaceutical Ingredient) Business
TypeHardware Sales
Description

Revenue from manufacturing and selling active pharmaceutical ingredients following merger with Daesung Pharmtech completed January 2026. Includes raw materials, wholesale, and reagent sales.

curacle.com
3Future Pipeline Licensing
TypeLicensing Royalties
Description

Planned out-licensing of remaining pipeline including CU01, CU06, MT-101, MT-201, MT-202. Revenue expected from upfront payments, milestone payments, and royalties.

curacle.com
4Veterinary Pharmaceutical (CP01-R01)
TypeOne Time License
Description

Companion animal CKD treatment expected to generate product revenue upon approval. Shorter development timeline than human pharmaceuticals.

curacle.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1MT-103 Licensing Deal Structure
ModelOtherBilling cadenceMulti-year contract
Notes

Total deal value up to $1,077,750,000 comprising $8M upfront, $82.25M development/regulatory milestones, $987.5M commercial milestones. 50:50 revenue split with MabTics. Curacle's net share: $4M upfront + milestone entitlement.

curacle.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Curacle develops first-in-class drug candidates that restore microvascular function in aging and chronic diseases, focusing on endothelial dysfunction. Its pipeline includes oral small molecules (Rivasterat/CU06, CU01, CU71) and antibody therapeutics (MT-101, MT-103, MT-105, MT-201, MT-202) for retinal, renal, neurodegenerative, and thrombotic diseases, plus a companion animal CKD candidate (CP01-R01). The company monetizes these assets primarily through global out-licensing deals with pharmaceutical partners and an API supply business.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • MT-103 demonstrated superior vascular stabilization and anti-angiogenic effects versus Vabysmo (faricimab) in head-to-head preclinical studies
+4 more records
Product overview1 text field

Curacle is a biopharmaceutical company developing first-in-class therapies restoring microvascular function in aging and chronic diseases. The company operates two technology platforms: SOLVADYS® for small molecule therapeutics and EAGLES® (in partnership with MabTics) for biologics. The pipeline includes eleven candidates across retinal diseases (Rivasterat/CU06, MT-103), renal diseases (CU01, MT-101, CP01-R01), neurodegenerative diseases (CU71), and cardiovascular/thrombotic conditions (MT-201, MT-202), with MT-103 successfully licensed to Memento Medicines in a $1.08 billion global deal.

Product and service1 record
1Rivasterat (CU06)
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Memento Medicines
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-05-01
Description

US-based NewCo biotech established for MT-103 development. Licensing deal worth up to $1.07775B for worldwide rights to bispecific antibody for retinal diseases. Memento raised $93M Series A. Founded by Sera Medicines and RA Capital. Supported by Forbion, RA Capital, Avego BioScience Capital, Sanofi Ventures, Samsara BioCapital.

curacle.com
2MabTics Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

Strategic partner for bispecific antibody development. Joint R&D agreement signed July 2024 covering 8 antibody pipeline programs including MT-101, MT-103, MT-201, MT-202, MT-105. Curacle holds 19.5% equity stake. Revenue from joint deals shared 50:50. MabTics operates EAGLES® antibody platform, spun off from KRIBB in 2022.

curacle.com
3Daesung Pharmtech (대성팜텍)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Completed absorption merger in January 2026. Merge ratio 1.0000000:15.5139384. Increased 620,557 shares, capital increase of KRW 310,278,500. Absorbed to internalize API business and establish stable revenue base.

curacle.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

MOU signed in April 2025 for comprehensive cooperation in API business. Daejung Pharma management invested in Curacle, becoming strategic investor and major shareholder. Aims to create synergy in API business expansion.

5Boryung (보령)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

MOU signed in September 2025 for CU01 Phase 3 development strategy and regulatory approval planning. R&D cooperation for clinical development advancement.

curacle.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Multiple preclinical studies conducted for MT-101 showing renal protection and fibrosis inhibition effects in kidney disease models.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage kidney disease biotech (acquired by Novartis in 2023 for up to $3.5B) that developed atrasentan for IgA nephropathy. Directly comparable to Curacle's CU01 program in diabetic nephropathy in target indication, mechanism, and trial design.

TypeDirect peer
Description

Clinical-stage biotech developing first-in-class therapies targeting integrin-mediated tissue fibrosis and vascular dysfunction. Directly comparable mechanism focus (vascular/endothelial pathology) and similar clinical-stage profile to Curacle's MT-101 and MT-202.

TypeDirect peer
Description

Commercial-stage biotech focused on rare kidney disease, with Filspari (sparsentan) approved for IgA nephropathy. Direct therapeutic-area competitor to Curacle's CU01 and MT-101 in diabetic nephropathy and related renal indications.

TypeEmerging player
Description

Clinical-stage biotech developing AV-101 (inhaled imatinib) for pulmonary arterial hypertension, a disease rooted in vascular endothelial dysfunction. Comparable mechanism focus on vascular pathology and similar small-cap clinical-stage profile.

TypeDirect peer
Description

Asset-centric biotech that develops and spins out individual drug candidates into subsidiary 'Vants' with dedicated funding — the same NewCo playbook Curacle used to launch Memento Medicines for MT-103. Comparable in building multiple platform-enabled programs around externally funded entities.

TypeDirect peer
Description

Multi-asset clinical-stage biotech operating multiple programs in parallel across rare and chronic diseases, with a similar strategy of advancing multiple first-in-class candidates until partnership or approval. Comparable in pipeline breadth, small team, and out-licensing orientation.

TypeDirect peer
Description

Clinical-stage gene therapy biotech developing intravitreal therapies (ADVM-022/ixoberogene soroparvovec) for wet AMD and diabetic retinopathy. Directly comparable to Curacle's retinal franchise (CU06, MT-103) in target indication and clinical-stage status.

TypeEmerging player
Description

Clinical-stage biotech developing abelacimab, a Factor XI inhibitor for non-bleeding antithrombotic therapy. Directly comparable to Curacle's MT-201/MT-202 'non-bleeding antithrombotic' positioning in mechanism rationale and target indication.

TypeDirect peer
Description

Clinical-stage retinal disease biotech developing next-generation anti-VEGF therapies (KSI-301/tarcocimab) for wet AMD and DME. Directly comparable to Curacle's CU06 and MT-103 in target indication and competitive landscape within retinal therapeutics.

TypeEmerging player
Description

UK-listed clinical-stage biotech developing multiple first-in-class small molecules in oncology and fibrosis with a similar multi-asset, platform-driven model. Comparable in size, pipeline breadth, and out-licensing/partnering strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curacle

Biopharmaceuticalscuracle.com

Curacle is a clinical-stage Korean biopharmaceutical company developing first-in-class small molecule and antibody therapies that restore microvascular function in retinal, renal, neurodegenerative, and thrombotic diseases, monetizing via out-licensing to global pharma and a newly integrated API business.

What Curacle does

Curacle Co., Ltd. is a clinical-stage Korean biopharmaceutical company founded in 2016 and listed on KOSDAQ (ticker 365270), headquartered in Seocho-gu, Seoul. It develops first-in-class therapies that restore microvascular function in aging and chronic diseases by targeting endothelial dysfunction, operating two proprietary platforms: the SOLVADYS® small-molecule platform and the EAGLES® antibody platform accessed through its strategic partner MabTics (in which Curacle holds a 19.5% equity stake). Its nine-asset pipeline spans retinal diseases (Rivasterat/CU06, MT-103), renal indications (CU01, MT-101, CP01-R01 for veterinary CKD), neurodegeneration (CU71 BBB stabilizer for Alzheimer's), inflammatory bowel disease (MT-105), and antithrombotics (MT-201, MT-202), with Rivasterat receiving the WHO INN in May 2025 (first '-sterat' class endothelial dysfunction blocker) and MT-103 demonstrating superior preclinical vascular stabilization versus Vabysmo (faricimab).

The company operates a capital-light out-licensing business model, executing global technology-transfer deals with pharmaceutical partners who fund development and commercialization. The flagship MT-103 bispecific antibody was licensed to US NewCo Memento Medicines in May 2026 in a deal valued up to $1.07775B (approximately 1.56 trillion KRW), with Curacle's 50% share through MabTics amounting to approximately $538.87M in attributable deal value. Curacle received $4M in cash plus $0.75M in Memento equity as the upfront share, with $82.25M in development/regulatory milestones and $987.5M in commercial milestones remaining. To diversify revenue beyond milestone-dependent licensing, Curacle completed an absorption merger with Daesung Pharmtech on January 28, 2026, internalizing an active pharmaceutical ingredient (API) business that supplies raw materials, wholesale, and reagents to pharmaceutical manufacturers. Additional revenue streams include veterinary product sales upon CP01-R01 approval, future licensing of CU01, CU06, MT-101, MT-201 and MT-202, and API manufacturing scale-up via the April 2025 MOU with Daejung Pharma.

Curacle firmographics

Firmographics
Name
Curacle
Legal name
Curacle Co., Ltd. (주식회사 큐라클)
Website
https://curacle.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Curacle is a clinical-stage Korean biopharmaceutical company developing first-in-class small molecule and antibody therapies that restore microvascular function in retinal, renal, neurodegenerative, and thrombotic diseases, monetizing via out-licensing to global pharma and a newly integrated API business.
Ownership category
akta.pro rank

Curacle industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Biopharmaceutical development
  • Microvascular therapeutics
  • Endothelial dysfunction drugs
  • Drug out-licensing
  • Clinical-stage biotechnology

Where Curacle is headquartered

Location

Headquarters

HQ city
Seocho
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Curacle business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing - MT-103: Up to $1.07775 billion deal with Memento Medicines including $8M upfront, up to $82.25M development/regulatory milestones, up to $987.5M commercial milestones. Curacle's 50% share amounts to $538.87M attributable revenue.
  2. API (Active Pharmaceutical Ingredient) Business: Revenue from manufacturing and selling active pharmaceutical ingredients following merger with Daesung Pharmtech completed January 2026. Includes raw materials, wholesale, and reagent sales.
  3. Future Pipeline Licensing: Planned out-licensing of remaining pipeline including CU01, CU06, MT-101, MT-201, MT-202. Revenue expected from upfront payments, milestone payments, and royalties.
  4. Veterinary Pharmaceutical (CP01-R01): Companion animal CKD treatment expected to generate product revenue upon approval. Shorter development timeline than human pharmaceuticals.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMT-103 Licensing Deal Structure

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Curacle product offering

Product offering

Core offering

Curacle develops first-in-class drug candidates that restore microvascular function in aging and chronic diseases, focusing on endothelial dysfunction. Its pipeline includes oral small molecules (Rivasterat/CU06, CU01, CU71) and antibody therapeutics (MT-101, MT-103, MT-105, MT-201, MT-202) for retinal, renal, neurodegenerative, and thrombotic diseases, plus a companion animal CKD candidate (CP01-R01). The company monetizes these assets primarily through global out-licensing deals with pharmaceutical partners and an API supply business.

Product overview

Curacle is a biopharmaceutical company developing first-in-class therapies restoring microvascular function in aging and chronic diseases. The company operates two technology platforms: SOLVADYS® for small molecule therapeutics and EAGLES® (in partnership with MabTics) for biologics. The pipeline includes eleven candidates across retinal diseases (Rivasterat/CU06, MT-103), renal diseases (CU01, MT-101, CP01-R01), neurodegenerative diseases (CU71), and cardiovascular/thrombotic conditions (MT-201, MT-202), with MT-103 successfully licensed to Memento Medicines in a $1.08 billion global deal.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rivasterat (CU06)

Quantifiable outcome

  • MT-103 demonstrated superior vascular stabilization and anti-angiogenic effects versus Vabysmo (faricimab) in head-to-head preclinical studies
  • +4 more outcomes

Companies that use Curacle

Customer profile

Named customers1 record

Segments6 records

Ideal customer profiles2 records

Curacle technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Curacle partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Memento MedicinescoreOEM/ Whitelabel/ Licensing Partner · 1 May 2026US-based NewCo biotech established for MT-103 development. Licensing deal worth up to $1.07775B for worldwide rights to bispecific antibody for retinal diseases. Memento raised $93M Series A. Founded by Sera Medicines and RA Capital. Supported by Forbion, RA Capital, Avego BioScience Capital, Sanofi Ventures, Samsara BioCapital.
  • MabTics Co., Ltd.coreStrategic or Co-development Partner · 1 July 2024Strategic partner for bispecific antibody development. Joint R&D agreement signed July 2024 covering 8 antibody pipeline programs including MT-101, MT-103, MT-201, MT-202, MT-105. Curacle holds 19.5% equity stake. Revenue from joint deals shared 50:50. MabTics operates EAGLES® antibody platform, spun off from KRIBB in 2022.
  • Daesung Pharmtech (대성팜텍)coreStrategic or Co-development PartnerCompleted absorption merger in January 2026. Merge ratio 1.0000000:15.5139384. Increased 620,557 shares, capital increase of KRW 310,278,500. Absorbed to internalize API business and establish stable revenue base.
  • Daejung Pharma (대정파마)minorStrategic or Co-development PartnerMOU signed in April 2025 for comprehensive cooperation in API business. Daejung Pharma management invested in Curacle, becoming strategic investor and major shareholder. Aims to create synergy in API business expansion.
  • Boryung (보령)minorStrategic or Co-development PartnerMOU signed in September 2025 for CU01 Phase 3 development strategy and regulatory approval planning. R&D cooperation for clinical development advancement.
  • Chungnam National University HospitalminorStrategic or Co-development PartnerMultiple preclinical studies conducted for MT-101 showing renal protection and fibrosis inhibition effects in kidney disease models.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Curacle competitors and assessment

Company assessment

Direct peers

  • Chinook Therapeutics: Clinical-stage kidney disease biotech (acquired by Novartis in 2023 for up to $3.5B) that developed atrasentan for IgA nephropathy. Directly comparable to Curacle's CU01 program in diabetic nephropathy in target indication, mechanism, and trial design.
  • Pliant Therapeutics: Clinical-stage biotech developing first-in-class therapies targeting integrin-mediated tissue fibrosis and vascular dysfunction. Directly comparable mechanism focus (vascular/endothelial pathology) and similar clinical-stage profile to Curacle's MT-101 and MT-202.
  • Travere Therapeutics: Commercial-stage biotech focused on rare kidney disease, with Filspari (sparsentan) approved for IgA nephropathy. Direct therapeutic-area competitor to Curacle's CU01 and MT-101 in diabetic nephropathy and related renal indications.
  • Roivant Sciences: Asset-centric biotech that develops and spins out individual drug candidates into subsidiary 'Vants' with dedicated funding — the same NewCo playbook Curacle used to launch Memento Medicines for MT-103. Comparable in building multiple platform-enabled programs around externally funded entities.
  • BridgeBio Pharma: Multi-asset clinical-stage biotech operating multiple programs in parallel across rare and chronic diseases, with a similar strategy of advancing multiple first-in-class candidates until partnership or approval. Comparable in pipeline breadth, small team, and out-licensing orientation.
  • Adverum Biotechnologies: Clinical-stage gene therapy biotech developing intravitreal therapies (ADVM-022/ixoberogene soroparvovec) for wet AMD and diabetic retinopathy. Directly comparable to Curacle's retinal franchise (CU06, MT-103) in target indication and clinical-stage status.
  • Kodiak Sciences: Clinical-stage retinal disease biotech developing next-generation anti-VEGF therapies (KSI-301/tarcocimab) for wet AMD and DME. Directly comparable to Curacle's CU06 and MT-103 in target indication and competitive landscape within retinal therapeutics.

Emerging players

  • Aerovate Therapeutics: Clinical-stage biotech developing AV-101 (inhaled imatinib) for pulmonary arterial hypertension, a disease rooted in vascular endothelial dysfunction. Comparable mechanism focus on vascular pathology and similar small-cap clinical-stage profile.
  • Anthos Therapeutics: Clinical-stage biotech developing abelacimab, a Factor XI inhibitor for non-bleeding antithrombotic therapy. Directly comparable to Curacle's MT-201/MT-202 'non-bleeding antithrombotic' positioning in mechanism rationale and target indication.
  • Redx Pharma: UK-listed clinical-stage biotech developing multiple first-in-class small molecules in oncology and fibrosis with a similar multi-asset, platform-driven model. Comparable in size, pipeline breadth, and out-licensing/partnering strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Curacle social profiles

Digital presence

Curacle compliance and trust

Trust signal

Compliance1 record

Curacle financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curacle leadership team

Management profile

Number of profiles

Profiles1 record

Curacle funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curacle M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curacle

What does Curacle do?

Curacle develops first-in-class drug candidates that restore microvascular function in aging and chronic diseases, focusing on endothelial dysfunction. Its pipeline includes oral small molecules (Rivasterat/CU06, CU01, CU71) and antibody therapeutics (MT-101, MT-103, MT-105, MT-201, MT-202) for retinal, renal, neurodegenerative, and thrombotic diseases, plus a companion animal CKD candidate (CP01-R01). The company monetizes these assets primarily through global out-licensing deals with pharmaceutical partners and an API supply business.

Is Curacle a public or private company?

Curacle is a public company. It is classified as public and is currently operating.

When was Curacle founded?

Curacle was founded in 2016. It employs 1 to 10 people.

Where is Curacle based?

Curacle is headquartered in Seocho, South Korea, in the Asia region.

How does Curacle make money?

Four revenue lines are on record. Technology Licensing - MT-103 is the primary driver. The others are API (Active Pharmaceutical Ingredient) Business, future Pipeline Licensing and veterinary Pharmaceutical (CP01-R01).

Who are Curacle's main competitors?

Direct peers on record are Chinook Therapeutics, Pliant Therapeutics, Travere Therapeutics, Roivant Sciences, BridgeBio Pharma, Adverum Biotechnologies and Kodiak Sciences. Emerging players are Aerovate Therapeutics, Anthos Therapeutics and Redx Pharma.

Does Curacle have an API?

No public API is recorded for Curacle.

What industry is Curacle in?

Curacle's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Memento Medicines Raises $93 Million Series A For Retinal Disease TherapyMemento Medicines announced the completion of a $93 million Series A financing round co-led by Forbion, RA Capital Management, and Avego BioScience Capital, with participation from Sanofi Ventures and Samsara BioCapital, to advance MMT-205, a bispecific antibody therapy for neovascular age-related macular degeneration and diabetic macular edema. The company also entered into an exclusive worldwide license agreement with MabTics and Curacle for the therapy, which targets both Tie2 activation and VEGF inhibition. Proceeds will fund IND-enabling studies, with clinical trials expected to begin in 2027.BioSpaceMemento brings home $93M series A souvenir, picks up bispecific for eye diseasesBoston-based biotech Memento Medicines has raised $93 million in Series A funding to develop a newly licensed bispecific antibody MMT-205 for retinal diseases. The company secured worldwide rights to the asset from MabTics and Curacle through an exclusive deal involving undisclosed upfront cash and equity, with plans to begin IND-enabling studies next year for conditions including neovascular age-related macular degeneration and diabetic macular edema. The funding round was co-led by Forbion, RA Capital Management, and Avego BioScience Capital, with participation from Sanofi Ventures and Samsara BioCapital.BioSpaceMemento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal DiseasesMemento Medicines closed a $93M Series A financing co-led by Forbion, RA Capital, and Avego BioScience Capital. The funds support IND-enabling studies for MMT-205, a bispecific antibody activating Tie2 and inhibiting VEGF, with clinical trials expected in 2027.GlobeNewswireMemento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal DiseasesMemento Medicines, a privately-held biotech company developing biologic therapies for retinal diseases, announced completion of a $93 million Series A financing round co-led by Forbion, RA Capital Management, and Avego BioScience Capital, with participation from Sanofi Ventures and Samsara BioCapital. The company also entered into an exclusive worldwide license agreement with MabTics Co., Ltd. and Curacle Co., Ltd. to develop MMT-205, a bispecific antibody that activates Tie2 and inhibits VEGF for treating neovascular age-related macular degeneration and diabetic macular edema. Proceeds will fund IND-enabling studies, with clinical trials expected to initiate in 2027.ChosunbizCuracle licenses retinal antibody MT-103 to US Memento in $1.08b dealCuracle signed a global technology transfer deal with U.S. biotech Memento Medicines for the bispecific antibody MT-103, a retinal disease treatment candidate co-developed with MapTx. The total deal value is up to $1,077.75 million (approximately 1.56 trillion won), with Curacle's attributable share at $538.87 million including upfront, development, regulatory, and commercial milestones. Under the agreement, Memento secures exclusive rights to global development, manufacturing, and commercialization of MT-103 for wet age-related macular degeneration and diabetic macular edema, with the possibility of expanding indications beyond retinal diseases.openPR.comDiabetic Kidney Disease Market: Expanding Revenue Landscape to 2034 - DelveInsight | Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth CorDelveInsight released a market forecast report for Diabetic Kidney Disease (DKD) covering 2020–2034, valued at approximately USD 7,200 million in 2023, projecting significant growth driven by rising disease prevalence and pipeline developments. Key developments include Renalytix's partnership with Tempus AI to expand kidneyintelX.dkd test access in the US, Bayer's clinical evidence reinforcing Kerendia (finerenone) benefits, and multiple Phase II trials underway by ZyVersa Therapeutics and Hua Medicine. The US accounted for approximately 5.1 million diagnosed DKD cases in 2023, representing the highest burden among the seven major markets studied.The Globe and MailDiabetic Kidney Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Mitsubishi Tanabe Pharma, PhytoHealthDelveInsight forecasts the diabetic kidney disease market to grow from $7.2 billion in 2023 to a higher value by 2034. The report covers epidemiology, drug uptake, and pipeline developments for major companies including Bayer, Pfizer, and Eli Lilly.